A functional 19-base pair deletion polymorphism of dihydrofolate reductase (DHFR) and risk of breast cancer in multivitamin users
Open Access
- 1 April 2007
- journal article
- research article
- Published by Elsevier in The American Journal of Clinical Nutrition
- Vol. 85 (4) , 1098-1102
Abstract
Background: Dihydrofolate reductase (DHFR) converts dihydrofolate (DHF) into tetrahydrofolate (THF) and plays an essential role in cell metabolism and cellular growth. Folic acid from multivitamins needs to be reduced by DHFR before it participates in cellular reactions. Objectives: We examined the relation of a 19-base pair (bp) deletion polymorphism of the DHFR gene with the risk of breast cancer by using data from the Long Island Breast Cancer Study Project, a population-based case-control study. We also investigated the transcriptional effect of this deletion polymorphism. Design: Dietary data and habitual use of multivitamins were assessed from a modified Block food-frequency questionnaire (FFQ). Genotypes of DHFR were ascertained from 1062 case subjects and 1099 control subjects by allele-specific polymerase chain reaction. Unconditional logistic regression was used to estimate odds ratios (ORs) and 95% CIs. Result: Although the DHFR 19-bp deletion polymorphism was not associated with overall breast cancer risk, we observed a borderline significant additive interaction (P = 0.06) between the DHFR genotype and multivitamin use. The −19-bp allele was associated with greater breast cancer risk in multivitamin users (51.2% of the study population) with an OR of 1.26 (95% CI: 0.96, 1.66) and 1.52 (95% CI: 1.08, 2.13) for the +/− and −/− genotypes, respectively (P for trend = 0.02) than in multivatimin nonusers. A dose-dependent relation (P for trend < 0.001) between DHFR expression and the deletion genotype was observed. Compared with the subjects with the 19-bp +/+ genotype, subjects with the −/− genotype had 4.8-fold DHFR mRNA levels. Conclusions: The DHFR 19-bp deletion polymorphism affects the transcription of DHFR gene in humans. Multivitamin supplements may place a subgroup of women (ie, those with the −19-bp allele) at elevated risk of developing breast cancer.Keywords
This publication has 16 references indexed in Scilit:
- Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening TrialThe American Journal of Clinical Nutrition, 2006
- Common dihydrofolate reductase 19–base pair deletion allele: a novel risk factor for preterm delivery1–3The American Journal of Clinical Nutrition, 2005
- New 19 bp deletion polymorphism in intron‐1 of dihydrofolate reductase (DHFR): A risk factor for spina bifida acting in mothers during pregnancy?American Journal of Medical Genetics Part A, 2003
- The Long Island Breast Cancer Study Project: Description of a Multi-Institutional Collaboration to Identify Environmental Risk Factors for Breast CancerBreast Cancer Research and Treatment, 2002
- Genotype transposer: automated genotype manipulation for linkage disequilibrium analysisBioinformatics, 2001
- Dietary Folate Intake, Alcohol, and Risk of Breast Cancer in a Prospective Study of Postmenopausal WomenEpidemiology, 2001
- Intake of food groups and associated micronutrients in relation to risk of early-stage breast cancerInternational Journal of Cancer, 1999
- A Prospective Study of Folate Intake and the Risk of Breast CancerJAMA, 1999
- Properties of Food Folates Determined by Stability and Susceptibility to Intestinal Pteroylpolyglutamate Hydrolase ActionThe Journal of Nutrition, 1998
- Increased Level of Dihydrofolic Reductase in Leucocytes of Patients Treated with AmethopterinNature, 1962